Do you want to read an article? Please log in or register.
Genomics Define Malignant Transformation in Myeloma Precursor Conditions
Multiple Myeloma (MM)
Indications
Related content
Multiple Myeloma (MM)
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma
J Clin Oncol
Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, Fan Y, Dakiki Korucu B, Szalat R, Fulciniti M, Anderson KC, Sperling A, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK
doi: 10.1200/JCO-25-00289
Multiple Myeloma (MM)
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing
Blood
Schavgoulidze A, Perrot A, Leleu X, Cazaubiel T, Chretien ML, Feugier P, Belhadj K, Manier S, Roussel M, Brechignac S, Orsini Piocelle F, Mohty M, Schiano de Colella JM, Macro M Dr, Adiko D, Dib M, Fontan J, Motard C, Bouscary D, Pascal L, Roland V, Lifermann F, Bakala JA, Montes L, Kennel C, Rey P, Richez V, Keddar F, Frenzel L, Calmettes C, Chaleteix C, Plantier I, Chalayer E, Schmitt A, Roul C, Demarquette H, Cerutti C, Pavageau L, Derrier L, Avet-Loiseau H, Corre J
doi: 10.1182/blood.2025029999
Multiple Myeloma (MM)
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma
Blood Cancer J
Yohannan B, Langworthy BW, Turner LE, Dispenzieri A, Buadi FK, Dingli D, Leung N, Kapoor P, Gonsalves WI, Kourelis T, Cook J, Binder M, Hayman SR, Lin Y, Go RS, Warsame RM, Rajkumar SV, Kumar S, Muchtar E, Alkhateeb HB, Hogan WJ, Matin A, Patnaik MM, Al-Kali A, Mangaonkar AA, Torghabeh M H, Wolf RC, Shah MV, Gertz MA
doi: 10.1038/s41408-026-01537-4
Multiple Myeloma (MM)
The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
Leuk Lymphoma
Park H, Robinson J, Flanagan C, Pawlyn C, Jackson G, Jones JR
doi: 10.1080/10428194.2025.2560085
Multiple Myeloma (MM)
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Clin Cancer Res
Suvannasankha A, Li M, Omofuma O, Hampp C, Phelan M, Breskin A, Shao P, Roccia T, Mukherjee N, Shrestha A, Lee D, Glass J, Kroog GS, Rodriguez Lorenc K
doi: 10.1158/1078-0432.CCR-25-4068
Multiple Myeloma (MM)
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium
Blood Cancer J
Portuguese AJ, Davis JA, Raza S, Castaneda Puglianini O, Freeman C, Alsina M, Wright C, Blue BJ, Baz RC, Shain KH, Goel U, Khouri J, Anwer F, Ali HM, Pasvolsky O, Gaballa M, Patel K, Garcia-Pleitez H, Mikulski D, Fogel L, Zolotov E, Sannareddy A, Afrough A, Anderson LD Jr, Julian K, Dima D, Banerjee R, Liang EC, Cassano Cassano R, Herr MM, Hassan H, Shune L, Kort J, Midha S, Nadeem O, Sidana S, Lin Y, Locke FL, Hansen DK, Sborov D, Biran N, Grajales-Cruz A
doi: 10.1038/s41408-026-01477-z
Multiple Myeloma (MM)
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma
Blood Cancer J
Kumar S, Jagannath S, Weisel KC, Rosiñol L, Leleu X, Dimopoulos MA, Kastritis E, Siegel DS, Monge J, Du J, de la Rubia J, Asensi Cantó P, Lee JH, Mateos MV, Puertas B, Gozzetti A, Dytfeld D, Ocio EM, Blade J, Ozaki S, Beksac M, Escalante F, Nagaraj M, Hassan R, Bonar N, Spin P, Shokoohi M, Siddiqui M, Wang D, Hou K, West MED, Hampp C, Green J, Humblet O, Breskin A, Harnett J, Ge W, Sobel RE, Jalbert JJ, Kroog GS, Rodriguez Lorenc K, Ma Q, Durie BGM
doi: 10.1038/s41408-026-01466-2
Multiple Myeloma (MM)
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy
Br J Haematol
Barilà G, Grassi A, Ruocco V, Liberatore C, Olivari E, Tinelli M, Fazio F, Morè S, Favero E, Cartia CS, Sgherza N, Conticello C, Mina R, Gherardini M, Mele G, Gentile M, Furlan A, Febbo MA, Del Giudice ML, Annibali O, Rossini B, Scomazzon E, Talarico M, Martino EA, De Magistris C, Fioritoni F, Cafro AM, Paris L, Pezzatti S, Della Pepa R, Boggione P, Pietrantuono G, Tomarchio V, Vassallo F, Pioltelli ML, Pisani F, Cagnetta A, De Paoli L, Buda G, Antonioli E, Galli M, Tosetto A, Musto P, Zamagni E, Patriarca F, Mangiacavalli S, Zambello R, Offidani M, Petrucci MT
doi: 10.1111/bjh.70751
Multiple Myeloma (MM)
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
Blood Cancer J
Afrough A, Dima D, Razzo B, Goel U, Sannareddy A, Pasvolsky O, Vazquez-Martinez MA, Ferreri CJ, Banerjee R, Khouri J, Davis JA, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Anwer F, Shune L, DeJarnette S, Grajales-Cruz AF, Ouchveridze E, De Avila G, Susanibar-Adaniya SP, Portuguese AJ, Schrum D, Eberwein E, Hosoya H, Mikkilineni L, Kaur G, McGuirk JP, Rossi A, Herr MM, Castaneda O, Locke FL, Raza S, Lin Y, Atrash S, Sborov DW, Voorhees PM, Richard S, Garfall AL, Sidana S, Patel KK, Hansen DK, Cowan AJ, Anderson LD Jr, Lee HC
doi: 10.1038/s41408-025-01414-6